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Refractory cardiac shock in the cardiac surgical intensive
care unit confers significant morbidity and mortality.
Extracorporeal membrane oxygenation (ECMO) has
become a common intervention for refractory
cardiogenic shock when other therapies have failed.
However, it is difficult to predict who will benefit from this
costly, resource-intensive, but potentially life-saving tech-
nology. Here, we discuss the utility of a novel biomarker,
serum butylcholinesterase, in determining survival in
patients supported with ECMO following cardiac surgery.complex operations, and pre-operative comorbidities areThe specter of post-cardiotomy shock haunts cardiac
surgeons and cardiac intensivists. Whether manifest as
failure to separate from cardiopulmonary bypass, persist-
ent low cardiac output with malperfusion, or sudden
hemodynamic collapse in the cardiac surgical intensive
care unit (CSICU), refractory cardiac shock confers
significant morbidity and mortality. When inotropes, vaso-
pressors, and intra-aortic balloon pumps fail, extracorporeal
membrane oxygenation (ECMO) has become a common
intervention for refractory cardiogenic shock. The work by
Distelmaier and colleagues [1] continues important work
aimed at determining who will benefit from this costly,
resource-intensive, but potentially life-saving technology.
Approximately 1% of all adult patients undergoing car-
diac surgery will experience post-cardiotomy shock [2].
ECMO has been used for post-cardiac surgical support
since the early 1990s [3], but with increasing frequency as
extracorporeal pumps, circuits, and oxygenators have im-
proved. However, outcomes are still poor; only about 25%
of patients supported with ECMO survive to hospital* Correspondence: eddy.fan@uhn.ca
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fractory cardiogenic shock, a subgroup of cardiac surgical
patients will clearly benefit from ECMO; the difficulty lies
in identifying this group of patients in a timely fashion.
Previous studies have attempted to identify predictors
of successful weaning from ECMO, predictors of mortal-
ity on ECMO, and predictors of long-term outcomes
after ECMO support [2,4-8]. The majority of these are
retrospective, and more than a decade old, limiting their
applicability to current ECMO technology. Factors
associated with poor outcomes after ECMO for post-
cardiotomy shock are not surprising: advanced age,
recurring themes. Distelmaier and colleagues should be
congratulated for designing a prospective biomarker
study to determine survival after ECMO.
Other groups have evaluated cardiac biomarkers as pre-
dictors of cardiac recovery during ECMO support with
disappointing results [9]. Distelmaier and colleagues chose
to examine levels of serum butyrylcholinesterase, which
has been studied extensively in the context of neuromus-
cular blockade, but more recently has been reported to
predict survival in cardiovascular and renal disease, albeit
in relatively small populations [10-12]. Even after account-
ing for age, comorbidities, and duration of ECMO sup-
port, higher butyrylcholinesterase levels were associated
with decreased mortality [1]. The mortality signal existed
both in the short-term (30 days) and the long-term (up to
6 years). The vast majority of deaths occurred in the first
year after ECMO implantation, highlighting that for those
who survive the initial ECMO experience, long-term out-
comes are reasonable. The patient population was modest
(191 patients), but typical of a tertiary cardiac surgical
practice, with isolated coronary artery bypass graft
(CABG) surgeries, valve procedures, CABG-valve opera-
tions, and transplants represented.
The mechanism by which butyrylcholinesterase medi-
ates the association with decreased mortality is not
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determinants of its level, nor the consequences of its defi-
ciency. Indeed, in a study of stroke patients, cholinesterase
activity was higher in patients than in matched controls
[13]. Because butyrylcholinesterase levels were determined
pre-operatively, it is not clear whether serum butyrylcho-
linesterase truly predicts ECMO-specific mortality, or
whether it is simply a marker for elevated cardiac risk, and
thus poor outcomes after cardiac surgery. Especially given
the lack of an identified mechanism, changes in butyryl-
cholinesterase may simply be an epiphenomenon of crit-
ical illness. Accordingly, the utility of butyrylcholinesterase
as a predictor of ECMO-specific mortality must be con-
firmed in future studies, and the biological mechanism
elucidated. It is also unknown whether butyrylcholinester-
ase levels would be predictive of outcomes in other appli-
cations of ECMO, such as in acute respiratory failure.
If butyrylcholinesterase levels truly predict ECMO-
specific outcomes, this biomarker could have significant
implications. Compared to other uses of ECMO (for ex-
ample, severe acute respiratory distress syndrome (ARDS)),
the decision to undertake ECMO support in post-
cardiotomy shock occurs in a compressed time frame.
Whereas patients with severe ARDS typically decline to
the point of requiring ECMO over a span of hours, post-
cardiotomy cardiac failure can occur suddenly: an unantici-
pated failure to separate from cardiopulmonary bypass or
an unheralded arrest in the CSICU. In the latter, there is
little time to calculate a prognostic score such as the PRE-
SERVE score proposed for ECMO and severe ARDS [14].
The ability to predict ECMO outcomes prior to surgery
would arm surgeons and intensivists with more data to
guide emergent decisions. Indeed, if this study’s findings
are confirmed, one can envision development of a pre-
operative 'game plan', with support options in the case of
refractory shock explicitly laid out. While the pre-
operative determination of appropriate support options
for a given patient has some appeal, would preclusion of
ECMO support based on a single pre-operative biomarker
be acceptable to physicians and patients? Therapeutic de-
cisions based on well-characterized biomarkers are com-
mon in other fields (for example, oncology) where
mechanistic rationale and extensive clinical data exist.
How strong must a biomarker, or indeed any prognostic
data, be in order to justify withholding of ECMO support
in an immediately life-threatening situation? These are im-
portant but unanswered questions. But as the cardiac sur-
gical population becomes more complicated, ECMO
technology improves, and mechanical circulatory support
for refractory post-cardiotomy shock becomes more com-
mon, it will become critical to develop a rational frame-
work for the use of this expensive and resource-intensive
treatment. Distelmaier and colleagues have made an im-
portant step towards answering this question: not whetherwe could, but whether we should utilize ECMO to support
a patient with post-cardiotomy shock.
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